Adjuvant therapy with somatostatin analogs for recurrent gastric neuroendocrine tumors type 1.

• DOI: 10.1200/jco.2025.43.4_suppl.665
• Publication Date: 2025-01-27T14:37:03Z
• Authors: Alla Anatolievna ...; Yaroslav Zhulikov; Ekaterina Evdokimova; Vera Gorbunova; Galina Emelianova; Kizler Gadzhieva; Olga Malikhova; Ivan Karasev; Vera Delektorskaya; Yuri Kuvshinov; Anna Kuznetsova; Elena Artamonova
• Keywords: Somatostatin Analogue

665 Background: Neuroendocrine gastric tumors (gNETs) type 1 are associated with chronic autoimmune atrophic gastritis, hypergastrinemia and usually have multifocal lesions high frequency of recurrence (up to 70% for 2 years). Somatostatin analogs (SA) showed promising data in neoadjuvant setting 84% complete responses a small retrospective trial. The aim this study was evaluate the efficacy adjuvant treatment SA recurrent gNETs 1. Methods: This retrospective, single-center included patients (pts) who received SA. Recruitment pts carried out from 2012 February 2024. Results: 35 pts, 33 females males. Endoscopic mucosal resection (EMR) performed 34 cases (97.1%), (2.9%). median previous EMR (1-6) procedures. Most – 28 (80%), is 5. tumor size 6 mm, >10 mm observed (5.7%), one them had N+. ki67 3,5% (1-10%), grade (G) - 14 (40%) G2 21 (60%). All therapy SA, (94.3%)long-active releasing octreotide30 mg (5.7%) lanreotide 120 every 4 weeks. time <12 months 23 (65.7%) ≥12 12 (34.3%). follow-up 30.5 months. disease-free survival (DFS) not reached (95% CI, 67-NR). We compared DFS after (DFS1) without (DFS2). DFS2 significantly higher DFS1 8.8 2.7-14.9) 67-NR, p<0.01) . Adjuvant improved 58.1-NR) versus 61 26.2-96.2, p=0.05). reduced gastrin levels year by ≥50% baseline 13 (37.1%). Conclusions: should be considered Duration improvement shorter duration therapy.